The US Food and Drug Administration is working to accelerate clinical development of manufactured, plasma-derived hyperimmune globulin therapeutics for COVID-19 while also enabling emergency use in seriously ill patients of raw plasma collected from donors who have recovered from the disease.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?